A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for 52 weeks with subcutaneous (s.c.) secukinumab (300 mg and 150 mg)

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for 52 weeks with subcutaneous (s.c.) secukinumab (300 mg and 150 mg)

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Biomarker; Pharmacodynamics; Registrational
  • Acronyms CARIMA
  • Sponsors Novartis
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 May 2016 Status changed from recruiting to completed.
    • 26 Sep 2015 New Source identified and integrated (ClinicalTrials.gov NCT02559622).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top